|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,300,931: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,300,931, granted on November 27, 2007, to Bristol-Myers Squibb, relates to a pharmaceutical composition comprising a BCL-2 inhibitor, specifically targeting apoptosis regulation in cancer therapy. The patent claims cover compositions, methods of treatment, and specific compounds related to BCL-2 inhibition, primarily focusing on anti-cancer applications. Its scope encompasses compounds structurally related to the claimed molecules, methods of extracting or synthesizing these compounds, and their use in treating cancers overexpressing BCL-2 proteins.
This patent landscape analysis dissects the patent's claims to elucidate its breadth, explores its influence on subsequent patent filings, and situates it within the broader field of apoptosis-targeted therapies. It offers a detailed overview for stakeholders evaluating patent risks, freedom-to-operate, or strategic R&D directions in BCL-2 inhibitors and related compounds.
1. Patent Summary and Core Claims
1.1 Patent Overview
- Title: "Polycyclic compounds as Bcl-2 inhibitors"
- Assignee: Bristol-Myers Squibb
- Filing Date: May 24, 2006
- Grant Date: November 27, 2007
- Priority: US Provisional Application filed on May 24, 2005
1.2 Main Patent Scope
The patent discloses heterocyclic compounds acting as BCL-2 protein inhibitors, useful in inducing apoptosis in cancer cells, with broad claims covering:
- Specific chemical structures of compounds
- Pharmaceutical compositions containing these compounds
- Methods of treating cancer using these compositions
- Processes for synthesizing the compounds
1.3 Key Claims Breakdown
- Claim 1: Composition claim covering a compound with a specific heterocyclic core structure, substituted at various positions.
- Claims 2-20: Dependent claims detailing preferred substituents, stereochemistry, and specific compounds.
- Claims 21-50: Methods of inhibiting BCL-2 activity in mammals, specifically in cancer therapies.
- Claims 51-60: Processes for preparing the compounds, including synthesis pathways.
2. Scope of the Patent: Detailed Analysis
2.1 Structural Scope
The core structure involves a polycyclic heteroaryl moiety designed to bind BCL-2 proteins. Variations permitted at multiple positions expand the scope significantly, allowing for numerous derivatives.
| Structural Variations |
Description |
Examples |
| Heterocyclic core |
Anthracene-like fused rings |
Benzothiophene, quinazoline |
| Substituents at R1 |
Alkyl, alkoxy, or amino groups |
Methyl, methoxy |
| R2 substitutions |
Halogen, methyl, or hydroxyl |
Chlorine, methyl |
2.2 Claim Breadth and Limitations
- Broad claims on polycyclic heteroaryl compounds with variable substitutions.
- Specific compounds are disclosed but claims do not limit themselves to the exact compounds, indicating a genus coverage.
- Method claims encompass treatment of cancers characterized by BCL-2 overexpression, notably leukemias and lymphomas.
2.3 Overlap with Existing Art
- Claims extend prior art by innovating a specific heterocyclic framework with potent BCL-2 inhibitory activity.
- Prior art (e.g., U.S. Patent 6,991,878) disclosed BCL-2 inhibitors with different scaffolds but the structure claimed here marked a significant invention step.
2.4 Patent Term and Patent Life
- Filed in 2006; expected expiration around 2026, assuming maintenance fees are paid.
- Provides a 20-year exclusivity window from filing, covering ongoing development and commercialization.
3. Patent Landscape and Industry Impact
3.1 Related Patents and Patent Families
Bristol-Myers Squibb (BMS) owns a patent family surrounding BCL-2 inhibitors, including:
- US Patent 7,300,931
- European Patent EP 1 872 739 B1 (related to similar compounds)
- Patent families cover compositions, methods, and synthesis protocols
3.2 Competitor Patent Filings
- AbbVie, Abbott, and AstraZeneca have filed patents targeting BCL-2 inhibition with different scaffolds (e.g., venetoclax patents).
- Venetoclax (Venclexta), a BCL-2 inhibitor approved in 2016, references early patents akin to 7,300,931, indicating its foundational role.
| Competitors |
Notable Patents |
Assignee |
Focus |
| AbbVie |
US Patent 8,070,543 |
AbbVie |
Selective BCL-2 inhibitors |
| AstraZeneca |
Multiple filings |
AstraZeneca |
BH3 mimetics |
3.3 Subsequent Innovations and Emerging Trends
- Developments focus on improving selectivity, potency, and pharmacokinetics.
- The scope of patents has shifted toward targeted therapies with reduced toxicity.
- Combination therapies with other agents (e.g., BTK inhibitors) enhance treatment efficacy.
3.4 Patent Challenges and Legal Status
- Litigation: Some patents in this space face validity challenges due to prior art overlaps.
- Licensing and Freedom to Operate (FTO): Companies must navigate overlapping claims, especially with compounds similar to venetoclax.
4. Comparative Analysis with Related Patents
| Aspect |
US Patent 7,300,931 |
US Patent 8,070,543 (A. v. AbbVie) |
US Patent 8,865,469 (Venetoclax) |
| Core Scaffold |
Polycyclic heteroaryl |
BH3 mimetics |
Benzothiazole derivatives |
| Focus |
BCL-2 inhibitors |
BCL-2/BCL-xL inhibitors |
Highly selective BCL-2 inhibitor |
| Specificity |
Broad genus claims |
Focused derivatives |
Approved drug with narrow claims |
| Date |
2007 |
2012 |
2014 (priority date) |
The 2007 patent predates venetoclax, underscoring its foundational role in BCL-2 inhibitor development.
5. Legal and Commercial Implications
5.1 Patent Strength
- Broad claims extend coverage over a wide chemical space.
- Synthesis process claims bolster enforceability.
- However, overlapping prior art could challenge validity.
5.2 Risk and Opportunity Assessment
- Companies developing BCL-2 inhibitors should evaluate the patent's scope vis-à-vis their compounds.
- License agreements or design-around strategies are essential for freedom-to-operate.
5.3 Market Positioning
- The patent supports early-stage development but requires complementary patents for specific compounds and formulations.
- Monopoly is likely limited once other patents, such as venetoclax’s, expire.
6. Frequently Asked Questions
Q1: How does U.S. Patent 7,300,931 influence current BCL-2 inhibitor development?
A1: It provides foundational breadth over heterocyclic BCL-2 inhibitors, serving as a key patent in early anti-apoptotic therapy development. However, newer patents with narrower claims, such as venetoclax, have since become more commercially relevant.
Q2: What are the limitations of the claims in Patent 7,300,931?
A2: The claims target a broad genus of compounds with various substitutions, which may be challenged if prior art demonstrates novelty issues. The patent does not cover specifically optimized or marketed compounds like venetoclax.
Q3: Are there any legal challenges or litigations related to this patent?
A3: No publicly documented litigations explicitly challenge this patent. Nonetheless, overlapping patents and prior art in the BCL-2 inhibitor space caution against potential disputes.
Q4: How does this patent compare to other BCL-2 inhibitors in terms of patent scope?
A4: Its scope is broader in chemical space, but later patents, especially those covering approved drugs like venetoclax, have more specific claims, possibly limiting their scope but increasing enforceability.
Q5: Can this patent still serve as a basis for licensing or collaboration?
A5: Yes, especially for compounds within its broad genus, but due diligence must assess claims scope, validity, and freedom-to-operate.
7. Key Takeaways
- U.S. Patent 7,300,931 grants broad protection over heterocyclic BCL-2 inhibitors, primarily in compositions and methods for cancer treatment.
- Its scope covers many potential compounds, making it significant in early-stage discovery but likely less controlling at the point of marketed drugs like venetoclax.
- The patent landscape for BCL-2 inhibitors is densely populated, with later patents focusing on more specific compounds or improved pharmacokinetic profiles.
- Strategic patent planning should account for the expiration timelines and overlapping claims, especially given the prominence of later patents with narrower scopes but higher commercial relevance.
- Companies must conduct comprehensive freedom-to-operate analyses incorporating this patent and related filings for ongoing or future development.
References
[1] U.S. Patent 7,300,931, "Polycyclic compounds as Bcl-2 inhibitors," Bristol-Myers Squibb, 2007.
[2] U.S. Patent 8,070,543, "BCL-2 inhibitors," AbbVie, 2012.
[3] U.S. Patent 8,865,469, "Selective BCL-2 inhibitors," AbbVie, 2014.
[4] Food and Drug Administration, "Venclexta (venetoclax) NDA review," 2016.
[5] L. Katre et al., "The role of BCL-2 family proteins in apoptosis and cancer," Nature Reviews Drug Discovery, 2013.
More… ↓
⤷ Start Trial
|
